Sarepta Therapeutics's latest marketcap:
As of 07/16/2025, Sarepta Therapeutics's market capitalization has reached $1.79 B. According to our data, Sarepta Therapeutics is the 6723th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.79 B |
| Revenue (ttm) | 2.23 B |
| Net Income (ttm) | -248,388,000 |
| Shares Out | 98.28 M |
| EPS (ttm) | -2.59 |
| Forward PE | 32.41 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/06/2025 |
Sarepta Therapeutics's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/16/2025 | $1.79 B | -84.62% | 6723 |
| 12/31/2024 | $11.61 B | 28.75% | 1498 |
| 12/29/2023 | $9.02 B | -20.7% | 1769 |
| 12/30/2022 | $11.37 B | 45.06% | 1364 |
| 12/31/2021 | $7.84 B | -41.72% | 2213 |
| 12/31/2020 | $13.45 B | 39.87% | 1248 |
| 12/31/2019 | $9.62 B | 31.9% | 1381 |
| 12/31/2018 | $7.29 B | 102.79% | 1500 |
| 12/29/2017 | $3.6 B | 140.16% | 3015 |
| 12/30/2016 | $1.5 B | -14.27% | 4875 |
Company Profile
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics, gene therapies, and genetic treatments for rare diseases.
Key Products
- EXONDYS 51: Treats Duchenne muscular dystrophy (Duchenne) in patients with exon 51-skippable mutations.
- VYONDYS 53: Targets Duchenne patients with exon 53-skippable mutations.
- AMONDYS 45: Designed for Duchenne patients with exon 45-skippable mutations.
- ELEVIDYS: A gene therapy for ambulatory pediatric Duchenne patients with confirmed mutations.
Pipeline & Collaborations
The company is advancing SRP-9003, a gene therapy program for limb-girdle muscular dystrophies. Sarepta has strategic partnerships with leading institutions and biopharmaceutical firms, including:
- F. Hoffman-La Roche Ltd
- Arrowhead Pharmaceuticals, Inc.
- University of Western Australia
- Nationwide Children’s Hospital
- Dyno Therapeutics
Founded: 1980 | Headquarters: Cambridge, Massachusetts
Frequently Asked Questions
-
What is Sarepta Therapeutics's (SRPT) current market cap?As of 07/16/2025, Sarepta Therapeutics (including the parent company, if applicable) has an estimated market capitalization of $1.79 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Sarepta Therapeutics (SRPT) rank globally by market cap?Sarepta Therapeutics global market capitalization ranking is approximately 6723 as of 07/16/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.